Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2024 Mar 28

PMID 38543764

Authors

Carolyn Chu

Kaiming Tao

Vinie Kouamou

Ava Avalos

Jake Scott

Philip M Grant

Soo-Yon Rhee

Suzanne M McCluskey

Michael R Jordan

Rebecca L Morgan

Robert W Shafer

Affiliations

Soon will be listed here.

Abstract

Background: Dolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART.

Methods: We performed a PubMed search using the term "Dolutegravir", last updated 18 December 2023, to estimate the prevalence of VF with emergent INSTI DRMs in people living with HIV (PLWH) without previous VF on an INSTI who received DTG-containing ART.

Results: Of 2131 retrieved records, 43 clinical trials, 39 cohorts, and 6 cross-sectional studies provided data across 6 clinical scenarios based on ART history, virological status, and co-administered ARVs: (1) ART-naïve PLWH receiving DTG plus two NRTIs; (2) ART-naïve PLWH receiving DTG plus lamivudine; (3) ART-experienced PLWH with VF on a previous regimen receiving DTG plus two NRTIs; (4) ART-experienced PLWH with virological suppression receiving DTG plus two NRTIs; (5) ART-experienced PLWH with virological suppression receiving DTG and a second ARV; and (6) ART-experienced PLWH with virological suppression receiving DTG monotherapy. The median proportion of PLWH in clinical trials with emergent INSTI DRMs was 1.5% for scenario 3 and 3.4% for scenario 6. In the remaining four trial scenarios, VF prevalence with emergent INSTI DRMs was ≤0.1%. Data from cohort studies minimally influenced prevalence estimates from clinical trials, whereas cross-sectional studies yielded prevalence data lacking denominator details.

Conclusions: In clinical trials, the prevalence of VF with emergent INSTI DRMs in PLWH receiving DTG-containing regimens has been low. Novel approaches are required to assess VF prevalence with emergent INSTI DRMs in PLWH receiving DTG in real-world settings.

Citing Articles

Comparative Analyses of Antiviral Potencies of Second-Generation Integrase Strand Transfer Inhibitors (INSTIs) and the Developmental Compound 4d Against a Panel of Integrase Quadruple Mutants.

Smith S, Zhao X, Hughes S, Burke Jr T Viruses. 2025; 17(1).

PMID: 39861910 PMC: 11768864. DOI: 10.3390/v17010121.

Patterns of HIV-1 Drug Resistance Observed Through Geospatial Analysis of Routine Diagnostic Testing in KwaZulu-Natal, South Africa.

Gounder L, Khan A, Manasa J, Lessells R, Tomita A, Pillay M Viruses. 2024; 16(10).

PMID: 39459966 PMC: 11512327. DOI: 10.3390/v16101634.

Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir.

Beck I, Boyce C, Bishop M, Vu Y, Fung A, Styrchak S Viruses. 2024; 16(7).

PMID: 39066324 PMC: 11281587. DOI: 10.3390/v16071162.

References

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P . Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017; 390(10107):2063-2072. DOI: 10.1016/S0140-6736(17)32299-7. View

Kamori D, Barabona G, Rugemalila J, Maokola W, Masoud S, Mizinduko M . Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey. J Antimicrob Chemother. 2023; 78(3):779-787. DOI: 10.1093/jac/dkad010. View

Nyaku A, Zheng L, Gulick R, Olefsky M, Berzins B, Wallis C . Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353. J Antimicrob Chemother. 2019; 74(5):1376-1380. PMC: 6477973. DOI: 10.1093/jac/dky564. View

Benade M, Maskew M, Juntunen A, Flynn D, Rosen S . Prior exposure to antiretroviral therapy among adult patients presenting for HIV treatment initiation or reinitiation in sub-Saharan Africa: a systematic review. BMJ Open. 2023; 13(11):e071283. PMC: 10660894. DOI: 10.1136/bmjopen-2022-071283. View

Orrell C, Hagins D, Belonosova E, Porteiro N, Walmsley S, Falco V . Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised,.... Lancet HIV. 2017; 4(12):e536-e546. DOI: 10.1016/S2352-3018(17)30095-4. View

Oldenbuettel C, Wolf E, Ritter A, Noe S, Heldwein S, Pascucci R . Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Antivir Ther. 2016; 22(2):169-172. DOI: 10.3851/IMP3082. View

Taiwo B, Marconi V, Berzins B, Moser C, Nyaku A, Fichtenbaum C . Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis. 2018; 66(11):1794-1797. PMC: 5961309. DOI: 10.1093/cid/cix1131. View

Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F . Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. J Int AIDS Soc. 2019; 22(1):e25227. PMC: 6340053. DOI: 10.1002/jia2.25227. View

Olearo F, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M . Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infect Dis. 2019; 6(10):ofz330. PMC: 6778427. DOI: 10.1093/ofid/ofz330. View

10.

van Wyk J, Orkin C, Rubio R, Bogner J, Baker D, Khuong-Josses M . Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials. J Acquir Immune Defic Syndr. 2020; 85(3):325-330. PMC: 7446981. DOI: 10.1097/QAI.0000000000002449. View

11.

Griesel R, Zhao Y, Simmons B, Omar Z, Wiesner L, Keene C . Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial. Lancet HIV. 2023; 10(7):e433-e441. PMC: 10322729. DOI: 10.1016/S2352-3018(23)00081-4. View

12.

Amuge P, Lugemwa A, Wynne B, Mujuru H, Violari A, Kityo C . Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Lancet HIV. 2022; 9(9):e638-e648. PMC: 9646993. DOI: 10.1016/S2352-3018(22)00163-1. View

13.

Rolle C, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M . Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks. Open Forum Infect Dis. 2023; 10(3):ofad101. PMC: 10034754. DOI: 10.1093/ofid/ofad101. View

14.

Palmier E, De Miguel R, Montejano R, Busca C, Mican R, Ramos L . Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study. HIV Med. 2023; 24(9):1013-1019. DOI: 10.1111/hiv.13500. View

15.

van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J . Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type.... Clin Infect Dis. 2020; 71(8):1920-1929. PMC: 7643745. DOI: 10.1093/cid/ciz1243. View

16.

Aboud M, Orkin C, Podzamczer D, Bogner J, Baker D, Khuong-Josses M . Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019; 6(9):e576-e587. DOI: 10.1016/S2352-3018(19)30149-3. View

17.

Wijting I, Lungu C, Rijnders B, van der Ende M, Pham H, Mesplede T . HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy. J Infect Dis. 2018; 218(5):688-697. DOI: 10.1093/infdis/jiy176. View

18.

Gantner P, Cuzin L, Allavena C, Cabie A, Pugliese P, Valantin M . Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. HIV Med. 2017; 18(9):704-708. DOI: 10.1111/hiv.12506. View

19.

Ngoufack Jagni Semengue E, Fokam J, Etame N, Molimbou E, Ambe Chenwi C, Takou D . Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model. Viruses. 2023; 15(1). PMC: 9866637. DOI: 10.3390/v15010018. View

20.

Vavro C, Ruel T, Wiznia A, Montanez N, Nangle K, Horton J . Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study. Antimicrob Agents Chemother. 2021; 66(1):e0164521. PMC: 8765298. DOI: 10.1128/AAC.01645-21. View